Insider · CIK 0001704317
Vlad Coric
ceoofficerdirector
Files at RVNC (Revance Therapeutics, Inc.), RPRX (Royalty Pharma plc), BHVN (Biohaven Ltd.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 13, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +7,614 | $0.00 | $0 | 10,798 | May 14, 2025 |
| Apr 21, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +3,184 | $0.00 | $0 | 3,184 | Apr 21, 2025 |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | UTender of shares Common Stock | -5,784 | $3.65 | $21k | 15,000 | Feb 6, 2025 |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | Feb 6, 2025 |
| Jan 5, 2025 | BHVN Biohaven Ltd. | MOption exercise Common Shares | +14,250 | $0.00 | $0 | 1,803,409 | Jan 7, 2025 |
| Jan 5, 2025 | BHVN Biohaven Ltd. | FTax withholding Common Shares | -6,805 | $38.64 | $263k | 1,796,604 | Jan 7, 2025 |
| Jan 5, 2025 | BHVN Biohaven Ltd. | AGrant or award Stock Options (Right to buy)derivative | +343,000 | $0.00 | $0 | 343,000 | Jan 7, 2025 |
| Jan 5, 2025 | BHVN Biohaven Ltd. | AGrant or award Restricted Share Unit Awardderivative | +57,000 | $0.00 | $0 | 57,000 | Jan 7, 2025 |
| Jan 5, 2025 | BHVN Biohaven Ltd. | MOption exercise Restricted Share Unit Awardderivative | -14,250 | $0.00 | $0 | 42,750 | Jan 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.